Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03299790
Other study ID # HITDCM01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 6, 2017
Est. completion date September 30, 2020

Study information

Verified date December 2020
Source Hasselt University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

According to data of the International Diabetes Federation (IDF), diabetes in general affects approximately 415 million people worldwide and this number is still increasing. Cardiovascular diseases, one of the major complications of diabetes, are the leading cause of mortality and morbidity in the diabetic population. One of the cardiovascular complications is diabetic cardiomyopathy, in which structural and functional changes occur in the heart impairing cardiac function. Exercise training has already proven the benefits on glycemic control in diabetes. This is also the case for the effects on cardiac function. However, as results are conflicting, it remains unclear which elements of exercise training should be focused on. For instance, high-intensity interval training (HIIT) is gaining interest as positive effects are already shown on glycemic control. Therefore, the potential of HIIT to improve cardiac function in diabetes should be investigated. Further on, the effects of exercise training on cardiac function are mainly investigated during rest by the use of transthoracic echocardiography. Therefore, as data are lacking, it remains unclear how the diabetic heart functions during exercise. The aim of the present study is to investigate the effects of different training modalities (e.g. HIIT) on heart function in diabetes both during rest and during exercise itself. Therefore, cardiac function will be evaluated by the use transthoracic (exercise) echocardiography. This will be combined by the evaluation of several biochemical parameters. The results will provide more insight in the pathology of diabetic cardiomyopathy as well as the potential of exercise training for this cardiovascular complication. Eventually, this research will contribute to the optimization of exercise programs for patients with diabetes.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date September 30, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 81 Years
Eligibility Inclusion Criteria: - type 2 diabetes patients: - BMI > 20kg/m² - diagnosis of T2DM as stated in guidelines of ADA (American Diabetes Association) - stable medication for at least 3 months - Healthy controls: - BMI > 20kg/m² - no diabetes Exclusion Criteria: - iron deficiency anemia - participation in another clinical trial - heart diseases: CAD (coronary artery disease), ischemia, valvular diseases, congenital heart diseases - neurological, pneumological, oncological, orthopedic disorders - diabetes complications: renal diseases, retinopathy

Study Design


Intervention

Other:
high-intensity interval exercise training (HIIT)
This program includes 24 weeks of exercise training and is divided in different phases (phase 1: week 1-2, equal to the MIT group, phase 2: week 3-6, 6 bouts of high-intensity exercise, phase 3: week 7-12, 7 bouts of high-intensity exercise, phase 4: week 13-24, 8 bouts of high-intensity exercise). The exercise training program consists of 3 exercise sessions per week (for 6 months).
moderate-intensity exercise training (MIT)
This program includes 24 weeks of exercise training and is not devided in phases. The exercise training program consists of 3 endurance exercise sessions per week (for 6 months). The total exercise volume equals the exercise volume of the HIIT group.

Locations

Country Name City State
Belgium Jessa Ziekenhuis Hasselt

Sponsors (2)

Lead Sponsor Collaborator
Hasselt University Jessa Hospital

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Transthoracic echocardiography (TTE) during excercise heart function during exercise by means of standard echocardiography: evaluation of diastolic and systolic function (mitral inflow pattern, ejection fraction, tissue doppler imaging, strain rate analyses,…) and cardiac structure (left ventricle mass, intraventricular wall mass,…) day 1
Primary Transthoracic echocardiography (TTE) during excercise heart function during exercise by means of standard echocardiography: evaluation of diastolic and systolic function (mitral inflow pattern, ejection fraction, tissue doppler imaging, strain rate analyses,…) and cardiac structure (left ventricle mass, intraventricular wall mass,…) month 3
Primary Transthoracic echocardiography (TTE) during excercise heart function during exercise by means of standard echocardiography: evaluation of diastolic and systolic function (mitral inflow pattern, ejection fraction, tissue doppler imaging, strain rate analyses,…) and cardiac structure (left ventricle mass, intraventricular wall mass,…) month 6
Primary Transthoracic echocardiography (TTE) during excercise heart function during exercise by means of standard echocardiography: evaluation of diastolic and systolic function (mitral inflow pattern, ejection fraction, tissue doppler imaging, strain rate analyses,…) and cardiac structure (left ventricle mass, intraventricular wall mass,…) month 12
Primary Transthoracic echocardiography (TTE) heart function in rest by means of standard echocardiography: evaluation of diastolic and systolic function (mitral inflow pattern, ejection fraction, tissue doppler imaging, strain rate analyses,…) and cardiac structure (left ventricle mass, intraventricular wall mass,…) day 1
Primary Transthoracic echocardiography (TTE) heart function in rest by means of standard echocardiography: evaluation of diastolic and systolic function (mitral inflow pattern, ejection fraction, tissue doppler imaging, strain rate analyses,…) and cardiac structure (left ventricle mass, intraventricular wall mass,…) month 3
Primary Transthoracic echocardiography (TTE) heart function in rest by means of standard echocardiography: evaluation of diastolic and systolic function (mitral inflow pattern, ejection fraction, tissue doppler imaging, strain rate analyses,…) and cardiac structure (left ventricle mass, intraventricular wall mass,…) month 6
Primary Transthoracic echocardiography (TTE) heart function in rest by means of standard echocardiography: evaluation of diastolic and systolic function (mitral inflow pattern, ejection fraction, tissue doppler imaging, strain rate analyses,…) and cardiac structure (left ventricle mass, intraventricular wall mass,…) month 12
Primary ECG (Electrocardiogram) during excercise ECG during excercise (an incremental exercise test on a cycle) month 3
Primary ECG (Electrocardiogram) during excercise ECG during excercise (an incremental exercise test on a cycle) month 12
Primary ECG (Electrocardiogram) ECG in rest month 3
Primary ECG (Electrocardiogram) ECG in rest month 12
Secondary Glycemic control glycemic concentrations, HbA1c levels, insulin sensitivity, inflammation, cardiac biomarkers day 1
Secondary Glycemic control glycemic control, insulin sensitivity, inflammation, cardiac biomarkers month 3
Secondary Glycemic control glycemic concentrations, HbA1c levels, insulin sensitivity, inflammation, cardiac biomarkers month 6
Secondary Glycemic control glycemic concentrations, HbA1c levels, insulin sensitivity, inflammation, cardiac biomarkers month 12
Secondary Insulin metabolism Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g) day 1
Secondary Insulin metabolism Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g) month 3
Secondary Insulin metabolism Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g) month 6
Secondary Insulin metabolism Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g) month 12
Secondary Cardiac function Cardiac biomarkers (brain-derived natriuretic peptide (BNP) levels, cardiac troponin levels) day 1
Secondary Cardiac function Cardiac biomarkers (BNP levels, cardiac troponin levels) month 3
Secondary Cardiac function Cardiac biomarkers (BNP levels, cardiac troponin levels) month 6
Secondary Cardiac function Cardiac biomarkers (BNP levels, cardiac troponin levels) month 12
Secondary Inflammation and oxidative stress C reactive protein (CRP) levels, tumor necrosis factor-(TNF)alpha levels, interleukin (IL)-10 (interleukin) levels, oxidative stress markers (superoxide dismutase (SOD), malondialdehyde (MDA), glutathione peroxidase (GPX)) day 1
Secondary Inflammation and oxidative stress CRP levels, TNF-alpha levels, IL-10 levels, oxidative stress markers (SOD, MDA, GPX) month 3
Secondary Inflammation and oxidative stress CRP levels, TNF-alpha levels, IL-10 levels, oxidative stress markers (SOD, MDA , GPX) month 6
Secondary Inflammation and oxidative stress CRP levels, TNF-alpha levels, IL-10 levels, oxidative stress markers (SOD, MDA, GPX) month 12
Secondary body composition body composition, measured using dual x-ray absorptiometry day 1
Secondary body composition body composition, measured using dual x-ray absorptiometry month 6
Secondary Maximal oxygen uptake (ml/O2/kg/min) exercise capacity measured using indirect calorimetry and an incremental bicycle exercise protocol day 1
Secondary Maximal oxygen uptake (ml/O2/kg/min) exercise capacity measured using indirect calorimetry and an incremental bicycle exercise protocol month 3
Secondary Maximal oxygen uptake (ml/O2/kg/min) exercise capacity measured using indirect calorimetry and an incremental bicycle exercise protocol month 6
Secondary Maximal oxygen uptake (ml/O2/kg/min) exercise capacity measured using indirect calorimetry and an incremental bicycle exercise protocol month 12
See also
  Status Clinical Trial Phase
Recruiting NCT03239366 - A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population Phase 2
Completed NCT04597229 - Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus N/A
Completed NCT03623139 - Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes N/A
Active, not recruiting NCT04599920 - Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life) N/A
Active, not recruiting NCT03422471 - Hypoglycemia and Autonomic Nervous System Function- B2 N/A
Completed NCT04382521 - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions N/A
Recruiting NCT04564391 - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins N/A
Recruiting NCT03458715 - The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Completed NCT02974504 - Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN) Phase 4
Completed NCT05053828 - Type 2 Diabetes With Antiplatelet Drugs
Not yet recruiting NCT03659383 - The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine Phase 4
Completed NCT03542240 - Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome N/A
Completed NCT03657537 - Effects of Ketone Bodies on Cognition in Type 2 Diabetes Phase 1
Completed NCT03979768 - Risk Assessment of Type 2 Diabetes in Pharmacies N/A
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Active, not recruiting NCT04994288 - A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients Phase 2/Phase 3
Completed NCT03290768 - Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3) N/A
Enrolling by invitation NCT04088851 - "The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes" N/A
Completed NCT03643783 - Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients